Here is a company report on Orion by Siltanen following Q3 :)\n\n> Orion’s Q3 was once again strong. Earnings clearly beat our estimates, and revenue was in line with expectations. The earnings beat was driven by stronger-than-expected growth in high-margin Nubeqa royalties. We are raising our earnings forecasts for the coming years as Nubeqa reaches its potential faster than anticipated. However, long-term forecasts remain largely unchanged, as they already factor in significant success for Nubeqa. We revise our target price to EUR 90 (previously EUR 87) in line with the forecast changes and reiterate our Reduce recommendation, as we believe the share valuation already prices in most of the potential for the coming years.\n\nOrion Q3'26: Jälleen vahva tulosneljännes - Inderes
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Oriola - Lääkkeiden ja terveystuotteiden tukkukaupan asiantuntija | 1095 | 263169 | October 29, 2026 | |
| Olvin tulevaisuuden näkymät -ketju | 667 | 192591 | October 22, 2026 | |
| Lääketeollisuuden teknologisia huipputuotteita etsimässä: tasaista tylsää vai vuoristorataa? | 1209 | 200224 | October 28, 2026 | |
| Nixu sijoituskohteena | 486 | 102520 | January 12, 2024 | |
| IDEXX Laboratories – Eläinterveyden edistäjä | 11 | 1309 | February 2, 2026 |